Abstract
Human epithelial kidney cells (HEK) were prepared to coexpress α1A, α2δ with different β calcium channel subunits and green fluorescence protein. To compare the calcium currents observed in these cells with the native neuronal currents, electrophysiological and pharmacological tools were used conjointly. Whole-cell current recordings of human epithelial kidney α1A-transfected cells showed small inactivating currents in 80 mM Ba2+ that were relatively insensitive to calcium blockers. Coexpression of α1A, βIb, and α2δ produced a robust inactivating current detected in 10 mM Ba2+, reversibly blockable with low concentration of ω-agatoxin IVA (ω-Aga IVA) or synthetic funnel-web spider toxin (sFTX). Barium currents were also supported by α1A, β2a, α2δ subunits, which demonstrated the slowest inactivation and were relatively insensitive to ω-Aga IVA and sFTX. Coexpression of β3 with the same combination as above produced inactivating currents also insensitive to low concentration of ω-Aga IVA and sFTX. These data indicate that the combination α1A, βIb, α2δ best resembles P-type channels given the rate of inactivation and the high sensitivity to ω-Aga IVA and sFTX. More importantly, the specificity of the channel blocker is highly influenced by the β subunit associated with the α1A subunit.
Keywords: human epithelial kidney cells, voltage-gated calcium channels, coexpression, Purkinje cells
After the initial description of P-type calcium channels in Purkinje cells (1, 2), and the subsequent designation of the Q-type calcium channels as a separate channel category (3), concern has arisen regarding their true distinctness. The issue at hand concerns the use of pharmacological or biophysical operational definitions as a sole requirement in channel characterization, especially given the functional significance of these moieties in central nervous system physiology and pathology. Indeed, the molecular elements for the native P- and Q-type channels remain unclarified (4, 5).
Presently the accepted nomenclature for voltage-gated calcium channels include L, N, P, Q, R, and T. These channels are multimeric structures consisting of a main pore-forming subunit (α1), which can implement calcium ion conductance on its own in heterologous expression systems (5, 6). In addition, two other subunits are important in the functioning of the channel, α2δ and β (7, 8). It has been shown that the α2δ subunit increases the amount of α1C subunit (L-type calcium channel) at the plasmalemma, whereas β subunits increase the opening probability of the calcium channels expressed by the α1C subunit (9). In the case of P- and Q-type channels it has been proposed, based on pharmacology (5, 10), molecular dissection experiments (11), and subcellular localization (12, 13), that the α1A subunit is the pore-forming component. Given that this subunit does not reproduce the functional properties of P and Q calcium currents on its own, we tested whether different β subunits in the presence of the constant α2δ subunit produced any differences in the electrophysiological and/or pharmacological properties of α1A currents in a mammalian expression system.
MATERIALS AND METHODS
Preparation of Human Epithelial Kidney (HEK) Cells Expressing Channel Proteins.
For transient expression of channel proteins, HEK 293T cells were grown in DMEM (GIBCO) supplemented with 10% fetal bovine serum, 100 units/ml of penicillin G, and 100 μg/ml of streptomycin (GIBCO), and plated at 50% confluence. The appropriate cDNAs (α1A, α2δ, βIb, β2a, β3, and green fluorescence protein) were subcloned into the mammalian expression vector pcDNA 3.1 (Invitrogen). All calcium channels subunits were a kind gift of T. Snutch (University of British Columbia, Vancouver). Green fluorescence protein was obtained from CLONTECH. Cells expressing channels were prepared by using DOTAP (Boehringer Mannheim) to introduce the recombinant vectors (1 μg each) by lipofection according to the manufacturer’s protocols. After transfection, cells were allowed to reach 70% confluence and then plated at a 1:5 ratio and recorded 8–24 hr later.
Electrophysiological Analysis.
Whole-cell recordings (14) were obtained from green fluorescent cells, which were observed with an excitation wavelength of 488 nM and emission of 515 nM at room temperature by using an Axopatch 200-A (Axon Instruments, Foster City, CA). Cells were maintained in an extracellular solution containing 135 mM NaCl, 3.5 mM KCl, 1.5 mM CaCl2, 1.0 mM MgCl2, 5.0 mM glucose, and 10 mM Hepes (pH adjusted to 7.35 with NaOH). For the recording of barium currents the external solution contained 142 mM tetraethylammonium (TEA)-Cl, 10 mM BaCl2, and 10 mM Hepes⋅CsOH (pH 7.35) “standard solution.” Experiments with high extracellular barium used 80 mM BaCl2, 12 mM TEA-Cl, 10 mM Hepes (TEA), 290 mOsm with sucrose, and liquid junction potential was measured and subtracted for generation of I–V plots (15). The patch clamp pipettes contained a solution of 110 mM CsMeSO4, 4.5 mM MgCl2, 10 mM EGTA, 8 mM ATP, and 10 mM Hepes (pH adjusted to 7.35 with CsOH) and showed resistances of 3–7 MΩ (typically 4 MΩ). Calcium currents were obtained in an extracellular solution of 40 mM CaCl2, 80 mM TEA-Cl, 10 mM Hepes⋅CsOH (pH 7.35), 290 mOsm. For these experiments pipette solution contained 2.0 mM EGTA, otherwise identical to that described. Seal resistance was typically 10 GΩ. Recordings were obtained with partial series resistance compensation (60–80%), and most of the cell capacitance canceled. The currents were low pass-filtered at 2–5 kHz by using an eight pole Bessel filter (Frequency Devices, Haverhill, MA) and digitized at 2.5–5 kHz. Subtraction of leak and remaining capacitance was obtained by using a P/4 protocol. For data acquisition and analysis and voltage clamp protocols we used the pclamp software (Axon Instruments). Drugs, as well as recording extracellular solutions, were applied locally by means of a blunt pipette (gravity flow). sFTX (1, 16, 17) was freshly prepared before using, and ω-Aga IVA (a gift from Pfizer) was stored at −20°C as stock solution (100 μM).
RESULTS
The Pharmacological Profile of the Current Expressed by α1A Subunit Varies Depending on its Associated β Subunit.
The effects of sFTX and ω-Aga IVA on expressed calcium currents were examined in HEK 293T cells transiently transfected with α1A, α2δ cDNAs with and without different β subunits cDNAs. Green fluorescence protein was used to identify transfected cells. Expression of the different combinations resulted in Ba2+ currents with characteristic electrophysiological properties (Fig. 1) in whole-cell mode (see also ref. 5). When α1A subunits were coexpressed with α2δ and βIb they produced a fast-activating inward Ba2+ current sensitive to submillimolar concentrations of sFTX. The dose–response curve (Fig. 2A) shows a IC50 of 410 μM with a saturating maximum block around 1.5 mM. Interestingly, higher extracellular Ba2+ concentration (80 mM, concentration commonly used in single-channel studies) shifted the sFTX dose–response curve (Fig. 3 C and D). These results were consistent with studies that report Ba2+ ions concentration dependence on sFTX block of P-like calcium currents expressed in Xenopus oocytes (16).
The kinetics of the sFTX block was rather slow, with a transient but consistent increase of current seconds after local bath application, followed by maximum inhibition 1–4 min later. sFTX block reversed on washout and had a time course of ∼20 sec, reaching a 60 +/− 15% of initial current in ∼20 sec. Saturating concentrations of sFTX produced a significant decrease of τ inactivation (τ inactivation at +20 mV before sFTX = 233 +/− 12 msec and 43.64 +/− 7 msec after sFTX n = 4) (see Fig. 2B), resembling an open-channel blockade. Local application of ω-Aga IVA produced a significant block at a concentration higher than 50 nM (Fig. 4A). This effect was similar at low and high extracellular Ba2+ concentrations in contrast to the effect of sFTX (Fig. 3 A and B). The kinetics of ω-Aga IVA block (slow onset of its action) was comparable to those observed in hippocampal, dorsal root ganglion, and cerebellar granule neurons (18). Current inhibition produced by ω-Aga IVA was partially reversible on toxin withdrawal after 5–15 min. The percentage of recovery varied widely between cells and had values between 10% and 35%. The rate and amount of recovery was modified by high amplitude (+150 mV) depolarizing steps (1 Hz of 30 pulses of 50 msec duration). Under this protocol α1A, βIb, α2δ currents recovered in 3–5 min to 40–55% of their initial value (Fig. 4C). This protocol has been shown to speed up recovery from ω-Aga IVA block for both P-type currents in cerebellar Purkinje cells and in α1A currents obtained by expression in Xenopus oocytes (2, 10).
Coexpression of α1A, β2a, α2δ subunits were relatively insensitive to submillimolar concentrations of sFTX, obtaining a 40% block at 1 mM local application of the toxin, with similar on and off kinetics as that observed for the combination α1A, α2δ, βIb. ω-Aga IVA at 50 nM did not produce any significant effect on the barium currents produced by this subunit combination. Effects were clearly observed only at concentrations higher than 100 nM (Fig. 4A). For instance, 500 nM produced a 90% inhibition of this current (Fig. 4B). The inhibition was reversible in 60% of the cells reaching a 26 +/− 10% recovery 8–12 min after toxin withdrawal, which increased to 40 +/− 15% after high depolarizing prepulses as illustrated in Fig. 4B.
The response to sFTX of the currents obtained by α1A, α2δ, and β3 was similar to that of the α1A, α2δ, and β2a combination (Fig. 4A), with similar block characteristics as those observed for the other subunit combinations tested. ω-Aga IVA at 100 nM did not produce any significant effect on the current. In the absence of β subunits α1A currents were detectable only in high extracellular Ba2+, and local application of sFTX produced a block only at high millimolar concentrations (∼30% at 5 mM). No significant effects were observed at lower concentration. On the other hand, 200 nM ω-Aga IVA produced a 30 +/− 15% inhibition.
Contribution of β Subunits to the Electrophysiological Properties of α1A Currents.
Expression of α1A, α2δ calcium channel subunits in heterologous expression systems produced barium or calcium currents that varied in amplitude and inactivation depending on which β subunit is present (5, 9). We explored if the β subunits affect other electrophysiological properties of the α1A subunit. Whole-cell recordings of HEK α1A, α2δ, and βIb transfected cells showed inward barium currents first seen at (−20 mV) with a peak current at −10 to 0 mV with a fast-activating kinetics (time to peak = 2.4 +/− 0.4 msec n = 12) (Fig. 1 A and C). The potential at which half of the channels were activated was calculated from a smooth curve fitted to the raw I–V data (I = G(xE)/{1+exp[(V-V1/2)/K]} (V50 = 6.92 +/− 1.2 mV and e fold value = 2.8). Inactivation was studied by single long trace pulses as well as by instantaneous onset currents as shown in Fig. 5 C and D. Inactivation was best-fit by a single exponential in both protocols, which generated similar results, although the rate of inactivation was rather variable between cells (τ inact to + 20 mV = 225 +/− 64 msec n = 12) (Fig. 5 C and D). α1A, α2δ, βIb barium currents were relatively stable, and in some cases no rundown was observed (rundown 20 +/− 14% n = 12). Recovery from inactivation demonstrated a fast partial recovery, which was little affected over periods of seconds, reaching a 68 +/− 8% of initial value at 8 sec (Fig. 5B).
Attempts to study the currents with calcium as the main charge carrier produced a progressive current decay, reaching close to a complete block within ∼6 min (Fig. 5E). Indeed, such current once having vanished in the presence of calcium, quickly returned in a Ba2+ environment. This result suggested that the α1A, α2δ, βIb channel protein complex undergoes calcium-induced calcium channel inhibition in a reversible fashion. Tail current analysis (n = 6) demonstrated a τ off rate to −80 mV = 0.57 +/− 0.07 msec, best-fit by a single exponential (Fig. 1G). α1A, α2δ, β2a produced a fast-activating IBa (time to peak = 2.26 +/− 0.6 msec) (Fig. 1D). This current also showed a high variability of the rate of inactivation; for instance, 50% of the cells (n = 14) did not inactivate during 500 msec whereas the rest of the cells had a τ inact at +20 mV = 860 +/− 300 msec, with a peak current at 0 to +10 mV (Fig. 1 A and D). Tail current to −80 mV was best-fit monoexponentially (τ off rate at −80 mV = 0.42 +/− 0.14 msec) (Fig. 1F).
Coexpression of the same α subunits with β3 subunit produced fast-activating (time to peak = 2.16 +/− 0.7 msec) currents inactivated with a τ inact to + 20 mV = 214 +/− 28 msec (n = 4) (Fig. 1 A and E). In the three combinations studied, α1A, α2δ, and the different β(s) calcium channel subunits, high extracellular Ba2+ (40–80 mM) produced a shift to the right of the I–V relationship (see Figs. 3 A and C and 5A).
DISCUSSION
The present set of results address the issue of the differences between P and Q channels. The issue of what defines a channel type becomes one of the questions to be examined. Our results suggest that the P and Q channels are indeed functional variances of the α1A subunit, this variance being determined by the associated β subunits. This conclusion is based on biophysical and pharmacological measurements of the macroscopic α1A, α2δ supported barium currents when associated with different β subunits. Indeed both ω-Aga IVA and sFTX block preferentially the α1A, βIb combination with an ID50 smaller than α1A, β2a, and β3, which otherwise have similar current/voltage relations. We conclude that the βIb-associated current is the closest to the native P/Q type current and pharmacology. However, the relatively slow inactivation differentiates it from the rapidly inactivating Q current, making the α1A, βIb, α2δ the most likely candidate for the P current.
Whereas the biophysical results are in agreement with previous findings (5, 9, 10) the pharmacological results are unexpected, as they demonstrate that the β subunits influence the pharmacological properties of the current. Because the β subunit is an intracellular moiety the results suggest that this subunit must induce an allosteric change on the α1A subunit that modifies its pharmacological sensitivity. This conclusion touches on issues of channel characterization. It is apparent from present results that the association of the α1A, α2δ, βIb structure mimics the biophysical and pharmacological properties of classical P, and to a lesser extent the Q channels. Furthermore, it has been identified as P-type calcium channel of cerebellar granular neurons (19) with different functional properties from the initially described P-type calcium channel in Purkinje cells. The granule cell variant of the P channel shows slow inactivation kinetics reaching 34% inactivation at +10 mV after 720 msec. Expression of α1A, α2δ, βIb in COS cells (20) supports a slower inactivating IBa I–V shifted to the right as well as a lower apparent KD (11 nM) for ω-Aga IVA, than the one reported in the present work. Nevertheless, the result supports the view that the combination α1A, α2δ, βIb as best replicating the properties of the native P-type channel. Concerning channel characterization the differences in the pharmacology and electrophysiological properties of α1A, βIb IBa in various heterologous expression systems (oocytes) (4, 5), COS cells (20), and HEK cells (present work) may reflect different cellular processing mechanism. Alternatively, they may be due to post-translational modifications and/or differences in the ionic strength used in the different preparations, because expression of the same α subunits with β3 in HEK cells (21) produced an I–V similar to the one found in this work.
Since the inhibition produced by ω-Aga IVA and sFTX on α1A, α2δ, β(s) currents reached a saturation level without total block and the classification of R-type calcium currents relies on the unblocked total calcium currents with a toxin cocktail, this finding opens the possibility that R-type current may represent one of the α1A, α2δ, β(s) combinations tested. This theme requires further experimentation.
In conclusion, the channels composed of α1A, α2δ, β-Ib are the most likely molecular counterpart of native P-type(s) channels. On the other hand, this structure does not reproduce the pharmacological properties of either P or Q channel exactly, as the sensitivity to sFTX and ω-Aga IVA for P-type channels is lower than for the α1A, α2δ, βIb channels in HEK cells, whereas in COS cells (20) the IV curve is shifted to the right. This finding indicates that other elements may be lacking in HEK cells, preventing the exact reproduction of the native channel properties.
Acknowledgments
This work was supported by National Institutes of Health Grants NS13742 to R.L. and NS30989 to B.R.
ABBREVIATIONS
- HEK
human epithelial kidney cells
- sFTX
synthetic funnel-web spider toxin
- ω-Aga IVA
ω-agatoxin IVA
References
- 1.Llinás R, Sugimori M, Lin J-W, Cherksey B. Proc Natl Acad Sci USA. 1989;86:1689–1693. doi: 10.1073/pnas.86.5.1689. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Mintz I, Adams M, Bean B. Neuron. 1992;9:85–95. doi: 10.1016/0896-6273(92)90223-z. [DOI] [PubMed] [Google Scholar]
- 3.Randall A, Tsien R. J Neurosci. 1995;15:2995–3012. doi: 10.1523/JNEUROSCI.15-04-02995.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Zhang J, Randall A, Ellinor P, Horne W, Sather W, Tanabe T, Schwarz T, Tsien R. Neuropharmacology. 1993;32:1075–1088. doi: 10.1016/0028-3908(93)90003-l. [DOI] [PubMed] [Google Scholar]
- 5.Stea A, Tomlinson J, Soong T, Bourinet E, Dubel S, Vincent S, Snutch T. Proc Natl Acad Sci USA. 1994;91:10576–10580. doi: 10.1073/pnas.91.22.10576. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Mori Y, Friedrich T, Kim M, Mikami A, Nakai J, Ruth P, Bosse E, Hofmann F, Floreckerzi V, Furuchi J, Mikoshiba K, Imoto K, Tanabe T, Numa S. Nature (London) 1991;350:398–402. doi: 10.1038/350398a0. [DOI] [PubMed] [Google Scholar]
- 7.Hofmann F, Biel M, Flockerzi V. Annu Rev Neurosci. 1994;17:399–418. doi: 10.1146/annurev.ne.17.030194.002151. [DOI] [PubMed] [Google Scholar]
- 8.Isom L, DeJongh K, Catterall W. Nature (London) 1994;12:1183–1194. [Google Scholar]
- 9.Shistik E, Ivanina T, Puri T, Hosey M, Dascal N. J Physiol. 1995;481:55–62. doi: 10.1113/jphysiol.1995.sp021029. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Sather W, Tanabe T, Zhang J, Mori Y, Adams M, Tsien R. Neuron. 1993;11:291–303. doi: 10.1016/0896-6273(93)90185-t. [DOI] [PubMed] [Google Scholar]
- 11.Gillard, S., Volsen, S., Smith, W., Beattie, R., Bleakman, D. & Lodge, D. (1997) Physiol. Soc. Abst. Marine Biol. Assn. 58.
- 12.Westenbroek R, Sakurai T, Elliot E, Hell J, Starr T, Snutch T, Catterall W. J Neurosci. 1995;15:6403–6418. doi: 10.1523/JNEUROSCI.15-10-06403.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Day N, Wood S, Ince P, Volsen S, Smith W, Slater C, Shaw P. J Neurosci. 1997;17:6226–6235. doi: 10.1523/JNEUROSCI.17-16-06226.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Hammill A, Marty A, Neher E, Sakmann B, Sigworth F. Pflügers Arch. 1981;391:85–100. doi: 10.1007/BF00656997. [DOI] [PubMed] [Google Scholar]
- 15.Neher E. Methods Enzymol. 1992;207:123–131. doi: 10.1016/0076-6879(92)07008-c. [DOI] [PubMed] [Google Scholar]
- 16.Lin J-W, Rudy B, Llinás R. Proc Natl Acad Sci USA. 1990;87:4538–4542. doi: 10.1073/pnas.87.12.4538. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Cherksey B, Sugimori M, Llinás R. Ann NY Acad Sci. 1991;635:80–89. doi: 10.1111/j.1749-6632.1991.tb36483.x. [DOI] [PubMed] [Google Scholar]
- 18.Pearson H, Sutton K, Scott R, Dolphin A. J Physiol. 1995;482:493–509. doi: 10.1113/jphysiol.1995.sp020535. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Tottene A, Moretti A, Pietrobon D. J Neurosci. 1996;16:6353–6363. doi: 10.1523/JNEUROSCI.16-20-06353.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Berrow N, Brice N, Tedder I, Page K, Dolphin C. Eur J Neurosci. 1997;9:739–748. doi: 10.1111/j.1460-9568.1997.tb01422.x. [DOI] [PubMed] [Google Scholar]
- 21.Brody D, Patil P, Mulle J, Snutch T, Yue D. J Physiol. 1997;499:637–644. doi: 10.1113/jphysiol.1997.sp021956. [DOI] [PMC free article] [PubMed] [Google Scholar]